<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7484576\results\search\disease\results.xml">
  <result pre="consistent with existing copyright protections.KHVI_0_1794685.pdf Abstract ABSTRACT The novel coronavirus" exact="disease" post="(COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)"/>
  <result pre="protections.KHVI_0_1794685.pdf Abstract ABSTRACT The novel coronavirus disease (COVID-19) caused by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has rapidly spread across"/>
  <result pre="Abstract ABSTRACT The novel coronavirus disease (COVID-19) caused by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has rapidly spread across the"/>
  <result pre="ABSTRACT The novel coronavirus disease (COVID-19) caused by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus-2 (SARS-CoV-2) has rapidly spread across the world."/>
  <result pre="The novel coronavirus disease (COVID-19) caused by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus-2 (SARS-CoV-2) has rapidly spread across the world. This"/>
  <result pre="agents. This review signifies the most available frontiers in the" exact="viral" post="vaccine development approaches to counter the COVID-19/SARS-CoV-2. KEYWORDS SARS-CoV2"/>
  <result pre="vaccine development approaches to counter the COVID-19/SARS-CoV-2. KEYWORDS SARS-CoV2 COVID-19" exact="respiratory" post="disease therapeutic regimens viral vaccines control precautions fig-count: table-count:"/>
  <result pre="development approaches to counter the COVID-19/SARS-CoV-2. KEYWORDS SARS-CoV2 COVID-19 respiratory" exact="disease" post="therapeutic regimens viral vaccines control precautions fig-count: table-count: ref-count:"/>
  <result pre="counter the COVID-19/SARS-CoV-2. KEYWORDS SARS-CoV2 COVID-19 respiratory disease therapeutic regimens" exact="viral" post="vaccines control precautions fig-count: table-count: ref-count: page-count: Introduction Several"/>
  <result pre="coronaviruses are prevalent in humans causing only colds and slight" exact="upper" post="respiratory infections. Nevertheless, the widespread outbreaks of coronavirus infections"/>
  <result pre="are prevalent in humans causing only colds and slight upper" exact="respiratory" post="infections. Nevertheless, the widespread outbreaks of coronavirus infections have"/>
  <result pre="slight upper respiratory infections. Nevertheless, the widespread outbreaks of coronavirus" exact="infections" post="have become increasingly pervasive in humans. The first pandemic"/>
  <result pre="first pandemic of the twenty-first century caused by the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) emerged in 2002â€&quot;2003. After a"/>
  <result pre="pandemic of the twenty-first century caused by the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) emerged in 2002â€&quot;2003. After a decade,"/>
  <result pre="of the twenty-first century caused by the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) emerged in 2002â€&quot;2003. After a decade, the"/>
  <result pre="(SARS-CoV) emerged in 2002â€&quot;2003. After a decade, the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) appeared, and infections continue to expand"/>
  <result pre="emerged in 2002â€&quot;2003. After a decade, the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) appeared, and infections continue to expand in"/>
  <result pre="decade, the Middle East respiratory syndrome coronavirus (MERS-CoV) appeared, and" exact="infections" post="continue to expand in the Middle East. Now, after"/>
  <result pre="with more devastating effects has again emerged,1,2 and the associated" exact="disease" post="COVID-19 has disseminated to over 200 different countries of"/>
  <result pre="SARS-CoV and MERS-CoV, respectively.6 Until now, there is a very" exact="limited" post="arsenal to fight against lethal infections with no officially"/>
  <result pre="there is a very limited arsenal to fight against lethal" exact="infections" post="with no officially registered vaccines or treatments to combat"/>
  <result pre="(angiotensin-converting enzyme 2) and might exhibit common pathogenic mechanisms and" exact="limited" post="cross-neutralizing antibodies.6,7 This acquaintance along with improved knowledge of"/>
  <result pre="and plays a significant role in the membrane fusion and" exact="viral" post="attachment to host cells. It also helps to induce"/>
  <result pre="viral attachment to host cells. It also helps to induce" exact="viral" post="neutralizing antibodies, which might inhibit interactions with the host"/>
  <result pre="for SARS-CoV.8-10 Anti-viral therapies Interferon-Î± (IFN-Î±) is a member of" exact="type I" post="interferons family that provides one of the frontlines of"/>
  <result pre="that provides one of the frontlines of host resistance against" exact="viral" post="invade and infectivity. IFN-Î± inhibits virus infection by direct"/>
  <result pre="of host resistance against viral invade and infectivity. IFN-Î± inhibits" exact="virus infection" post="by direct interference with the replication cycle and boosting"/>
  <result pre="host resistance against viral invade and infectivity. IFN-Î± inhibits virus" exact="infection" post="by direct interference with the replication cycle and boosting"/>
  <result pre="interference with the replication cycle and boosting up innate and" exact="acquired" post="immune responses to infection. In-vitro trials-based studies revealed the"/>
  <result pre="have been found to be less vulnerable and protected from" exact="infectious diseases" post="caused by SARS-CoV.13 Furthermore, the therapeutic benefits of synthetic"/>
  <result pre="the outcome of MERS-CoV or SARS-CoV infected patients by ameliorating" exact="acute" post="respiratory distress syndrome (ARDS).18-20 A comparative illustration of healthy"/>
  <result pre="outcome of MERS-CoV or SARS-CoV infected patients by ameliorating acute" exact="respiratory" post="distress syndrome (ARDS).18-20 A comparative illustration of healthy and"/>
  <result pre="MERS-CoV or SARS-CoV infected patients by ameliorating acute respiratory distress" exact="syndrome" post="(ARDS).18-20 A comparative illustration of healthy and infected alveolus"/>
  <result pre="MERS-CoV, lopinavir-ritonavir could exhibit a beneficial impact to encounter COVID-19" exact="infectious disease." post="However, additional investigations are required to elucidate this opportunity."/>
  <result pre="A comparative illustration of healthy and infected alveolus due to" exact="Acute" post="Respiratory Distress Syndrome (ARDS). The Figure was created with"/>
  <result pre="comparative illustration of healthy and infected alveolus due to Acute" exact="Respiratory" post="Distress Syndrome (ARDS). The Figure was created with â€œBioRender.comâ€�"/>
  <result pre="of healthy and infected alveolus due to Acute Respiratory Distress" exact="Syndrome" post="(ARDS). The Figure was created with â€œBioRender.comâ€� template and"/>
  <result pre="in blend with other drugs when used for dealing with" exact="pneumonia" post="caused by SARS-CoV-2.22-26 Presently, many clinical control trials are"/>
  <result pre="suppress SARS-CoV and MERS-CoV in vivo.27,28 It strappingly prevented SARS-CoV-2" exact="infection" post="in a recent in vitro investigation at low-micro molar"/>
  <result pre="of remdesivir.29 Though remdesivir exhibits many merits for curing SARS-CoV-2" exact="infection" post="and pneumonia, randomized controlled trials (RCTs) are still necessitated"/>
  <result pre="medications is not recommended at the same time, and the" exact="consumption" post="of these therapeutic drugs should be discontinued in case"/>
  <result pre="cinanserin can be a suitable therapeutic option for suppressing the" exact="infection" post="caused by SARS-CoV-2. Flavonoids are an imperative group of"/>
  <result pre="promising anti-viral effects. Jo et al.35 revealed that the antiâ€�corona" exact="viral" post="properties of bioactive flavonoids, including rhoifolin, Herbacetin, and pectolinarin"/>
  <result pre="may be picked as alternative therapeutic options in combating COVIDâ€�19-induced" exact="infections" post="via targeting coronavirus proteases.24 Spike (S) protein-angiotensin converting enzyme-2"/>
  <result pre="(S) protein-angiotensin converting enzyme-2 (ACE2) blockers Angiotensinâ€�converting enzymeâ€�2 (ACE2), a" exact="type I" post="essential membrane protein, catalyzes the role of a carboxypeptidase."/>
  <result pre="target cells via binding with spike (S) glycoprotein.37 As a" exact="type I" post="surface protein, S protein is associated with the attachment"/>
  <result pre="cell receptors and intervenes in the fusion of host and" exact="viral" post="membranes.38 Human monoclonal antibody Monoclonal antibodies (mAbs) characterize a"/>
  <result pre="major class of bio-therapeutic products as passive immunotherapies in combating" exact="viral" post="infections. Figure 2 shows a stepwise illustration of the"/>
  <result pre="The therapeutic uses of mAbs have been widely accepted and" exact="acquired" post="remarkable achievements in the treatment of numerous chronic and"/>
  <result pre="accepted and acquired remarkable achievements in the treatment of numerous" exact="chronic" post="and lethal viral diseases.39 From the two nonimmune human"/>
  <result pre="remarkable achievements in the treatment of numerous chronic and lethal" exact="viral" post="diseases.39 From the two nonimmune human antibody libraries, Sui"/>
  <result pre="has been known to be a potent inhibitor of SARS-CoV-induced" exact="infectious disease" post="by disrupting ACE2, which is important binding regions on"/>
  <result pre="been known to be a potent inhibitor of SARS-CoV-induced infectious" exact="disease" post="by disrupting ACE2, which is important binding regions on"/>
  <result pre="track promotes its assessment in human patients infected with SARS-CoV-2" exact="disease" post="(COVID-19).44 Emodin is a natural anthraquinone compound that can"/>
  <result pre="Thus, it is thought that emodin could eliminate SARSâ€�CoV triggered" exact="disease" post="conditions by acting as a competitor for the same"/>
  <result pre="The investigation portrays that promazine and emodin might inhibit SARSâ€�CoV" exact="disease" post="by interfering with the binding of ACE2 and S"/>
  <result pre="no vaccines have been approved in humans to combat coronavirus-induced" exact="respiratory" post="infections. Only IBV vaccines have been registered in animals"/>
  <result pre="vaccines have been registered in animals for the management of" exact="upper" post="respiratory-tract infections of CoV in chickens.56,57 Since the COVID-19"/>
  <result pre="been registered in animals for the management of upper respiratory-tract" exact="infections" post="of CoV in chickens.56,57 Since the COVID-19 shares substantial"/>
  <result pre="BALB/c mice 32265331 PMC7157776 Li et al.31 Vector vaccine Modified" exact="vaccinia" post="virus Ankara (MVA)-based vaccine S protein No 32325037 PMC7172913"/>
  <result pre="DNA vaccine, Recombinant pcDNA3.1-S S protein Six-to eight-week-old specific pathogen-free" exact="female" post="BALB/c mice 28314561 PMC5411280 Chi et al.50 DNA vaccine,"/>
  <result pre="DNA vaccine, Recombinant pcDNA3.1-SÎ&quot;CD S protein Six-to eight-week-old specific pathogen-free" exact="female" post="BALB/c mice 28314561 PMC5411280 Chi et al.50 DNA vaccine,"/>
  <result pre="DNA vaccine, Recombinant pcDNA3.1-S1 S protein Six-to eight-week-old specific pathogen-free" exact="female" post="BALB/c mice 28314561 PMC5411280 Chi et al.50 DNA vaccinelive-attenuatedÂ"/>
  <result pre="DNA vaccinelive-attenuatedÂ S. typhimurium pcDNA-N N protein Yes â€&quot; Eight-week-old" exact="female" post="BALB/c mice 19186202 PMC7115532 Hu et al.51 DNA vaccine"/>
  <result pre="DNA vaccine pcDNA-S S protein Yes â€&quot; Six- to 8-week-old" exact="female" post="BALB/c mice 17494640 PMC1951058 Hu et al.52 DNA vaccine"/>
  <result pre="DNA vaccine pcDNA-IL-2 S protein Yes â€&quot; Six- to 8-week-old" exact="female" post="BALB/c mice 17494640 PMC1951058 Hu et al.52 DNA vaccine"/>
  <result pre="pcDNA-S +Â pcDNA-IL-2 S protein Yes â€&quot; Six- to 8-week-old" exact="female" post="BALB/c mice 17494640 PMC1951058 Hu et al.52 DNA vaccine"/>
  <result pre="DNA vaccine pcDNA3.1 S protein Yes â€&quot; Six- to 8-week-old" exact="female" post="BALB/c mice 17494640 PMC1951058 Hu et al.52 DNA vaccine"/>
  <result pre="DNA vaccine PBS S protein Yes â€&quot; Six- to 8-week-old" exact="female" post="BALB/c mice 17494640 PMC1951058 Hu et al.52 DNA vaccine"/>
  <result pre="DNA vaccine CS022 S protein Yes â€&quot; Six- to 8-week-old" exact="female" post="BALB/c mice 17494640 PMC1951058 Hu et al.52 DNA vaccine"/>
  <result pre="DNA vaccine N protein DNA vaccine N protein Yes â€&quot;" exact="Female" post="Balb/c mice 16423399 PMC7112551 Shi et al.53 DNA vaccine"/>
  <result pre="DNA vaccine M protein DNA vaccine M protein Yes â€&quot;" exact="Female" post="Balb/c mice 16423399 PMC7112551 Shi et al.53 DNA vaccine"/>
  <result pre="+Â M protein DNA vaccine N, M proteins Yes â€&quot;" exact="Female" post="Balb/c mice 16423399 PMC7112551 Shi et al.53 DNA vaccine"/>
  <result pre="vaccine N protein DNA vaccine N protein Yes â€&quot; Six-week-old" exact="female" post="BALB/c mice 15582659 PMC7111813 Zhao et al.55 The newer"/>
  <result pre="fall into following types such as inactive or live-attenuated viruses," exact="viral" post="vectors, virus-like particle (VLP), DNA-based, mRNA-based, and protein-based vaccines.58"/>
  <result pre="(VLP), DNA-based, mRNA-based, and protein-based vaccines.58 It is documented that" exact="viral" post="S protein subunit vaccines generate elevated titers of neutralizing"/>
  <result pre="approximately half of the patented reports have focused on the" exact="viral" post="S protein subunit vaccine and those explicitly directing the"/>
  <result pre="vaccines Live-attenuated CoV vaccines are produced by reverse genetics from" exact="infectious" post="virus clones by deleting numerous key pathogenicity factors to"/>
  <result pre="constructing a temperature-sensitive virus mutant with replication constrained to the" exact="upper" post="respiratory tract, and then generate additionally-conserved attenuated mutations by"/>
  <result pre="a temperature-sensitive virus mutant with replication constrained to the upper" exact="respiratory" post="tract, and then generate additionally-conserved attenuated mutations by applying"/>
  <result pre="tested mice after intracerebral vaccination. Virus-like particle or subunits vaccines" exact="Viral" post="subunits or virus-like particles vaccines provide universal and useful"/>
  <result pre="protein or receptor-binding domain subunit vaccines and replicating or non-replicating" exact="viral" post="vector-based vaccines with the expression of large spike protein"/>
  <result pre="with the expression of large spike protein or receptor-binding domain.62" exact="Patent" post="application WO2015042373 revealed an immunogenic preparation comprising MERS-CoV nanoparticles"/>
  <result pre="effectiveness heterologous prime-boost (inactivated virus particles, S/S1 proteins, and recombinant" exact="viral" post="vectors) regimens.8,9,60 However, the administration of DNA vaccine by"/>
  <result pre="up immunological responses, predominantly antigen-specific CD8+ T-cell-assisted responses against SARS-CoV" exact="infection" post="are documented in patent application WO2005081716.65 Immune responses, particularly"/>
  <result pre="cell-mediated immune and nucleocapsid-specific humoral responses. The titer of a" exact="vaccinia" post="vector with the expression of N protein of the"/>
  <result pre="by Moderna demonstrated mRNA vaccines consists of mRNAs encoding antigenic" exact="viral" post="full-length S, S1, or S2 proteins from MERS-CoV and"/>
  <result pre="well as specific neutralizing antibody responses in studied animal models." exact="Patent" post="application US20060002 947 unveils the formulation methodology for Ii-Key/MHC"/>
  <result pre="its patented Ii-Key immune system activation technology to manufacture COVID-19" exact="viral" post="peptide for human experimental trials.71 COVID-19 vaccine strategies depending"/>
  <result pre="humans, immunological protection correlation, and the time duration of naturally" exact="acquired" post="immunity would benefit the development of COVID-19 vaccination approaches"/>
  <result pre="the virus. Comprehensive knowledge of the SARS-CoV-2 pathogenesis, including the" exact="infection" post="of target organs and the route and mechanism of"/>
  <result pre="protection of target organs. For example, if the SARS-CoV-2 causes" exact="pneumonia" post="via upper respiratory tract infection, the use of vaccine"/>
  <result pre="target organs. For example, if the SARS-CoV-2 causes pneumonia via" exact="upper respiratory tract infection," post="the use of vaccine preparations containing live replication-competent vectors"/>
  <result pre="organs. For example, if the SARS-CoV-2 causes pneumonia via upper" exact="respiratory" post="tract infection, the use of vaccine preparations containing live"/>
  <result pre="to induce local mucosal immune response can protect both the" exact="upper" post="as well as lower respiratory tract infections and causes"/>
  <result pre="immune response can protect both the upper as well as" exact="lower" post="respiratory tract infections and causes a significant reduction in"/>
  <result pre="response can protect both the upper as well as lower" exact="respiratory" post="tract infections and causes a significant reduction in nasal"/>
  <result pre="protect both the upper as well as lower respiratory tract" exact="infections" post="and causes a significant reduction in nasal shedding. On"/>
  <result pre="reduction in nasal shedding. On the other hand, if the" exact="infection" post="occurs in the lungs or other organs through viremia,"/>
  <result pre="to prevent viremia. Furthermore, people who have recovered from COVID-19" exact="infection" post="but are again primed to the virus-like seasonal influenza,"/>
  <result pre="and B-cell mediated immunity responses, and may aid in preventing" exact="viral" post="reinfections. In some COVID-19 patients, diarrhea and fecal shedding"/>
  <result pre="may aid in preventing viral reinfections. In some COVID-19 patients," exact="diarrhea" post="and fecal shedding were observed,72 and these conditions can"/>
  <result pre="be changed if the virus attacks both the enteric and" exact="respiratory" post="tracts and is also shedding in the stool of"/>
  <result pre="vaccine prime might be the optimal candidates for preventing both" exact="respiratory" post="and intestinal infections, as well as blocking nasal and"/>
  <result pre="protect themselves and avoid getting sick? Are the currently available" exact="viral" post="vaccine development approaches good enough to tackle SARS-CoV-2, effectively?"/>
  <result pre="2020 422]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200421-sitrep-92-covid-19.pdf?sfvrsn=38e6b06d_4. 4.GorbalenyaAE, BakerSC, BaricR, GrootRJD, DrostenC, GulyaevaAA, PenzarDSevere" exact="acute" post="respiratory syndrome-related coronavirus: the species and its virusesâ€&quot;a statement"/>
  <result pre="422]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200421-sitrep-92-covid-19.pdf?sfvrsn=38e6b06d_4. 4.GorbalenyaAE, BakerSC, BaricR, GrootRJD, DrostenC, GulyaevaAA, PenzarDSevere acute" exact="respiratory" post="syndrome-related coronavirus: the species and its virusesâ€&quot;a statement of"/>
  <result pre="contained?Science. 2020;367(6478):610â€&quot;11. doi:10.1126/science.367.6478.610.32029604 6.ZhouP, YangXL, WangXG, HuB, ZhangL, ZhangW, ChenHDA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="Nature. 2020;579(7798):270â€&quot;73. doi:10.1038/s41586-020-2012-7.32015507 7.BilalM, NazirMS, Parra-SaldivarR, IqbalHMN2019-nCoV/COVID-19 - approaches to" exact="viral" post="vaccine development and preventive measures. J Pure Appl Microbiol."/>
  <result pre="doi:10.22207/JPAM.14.1.05. 8.EnjuanesL, DeDiegoML, Ã�lvarezE, DemingD, SheahanT, BaricRVaccines to prevent severe" exact="acute" post="respiratory syndrome coronavirus-induced disease. Virus Res. 2008;133(1):45â€&quot;62. doi:10.1016/j.virusres.2007.01.021.17416434 9.RoperRL,"/>
  <result pre="8.EnjuanesL, DeDiegoML, Ã�lvarezE, DemingD, SheahanT, BaricRVaccines to prevent severe acute" exact="respiratory" post="syndrome coronavirus-induced disease. Virus Res. 2008;133(1):45â€&quot;62. doi:10.1016/j.virusres.2007.01.021.17416434 9.RoperRL, RehmKESARS"/>
  <result pre="DeDiegoML, Ã�lvarezE, DemingD, SheahanT, BaricRVaccines to prevent severe acute respiratory" exact="syndrome" post="coronavirus-induced disease. Virus Res. 2008;133(1):45â€&quot;62. doi:10.1016/j.virusres.2007.01.021.17416434 9.RoperRL, RehmKESARS vaccines:"/>
  <result pre="Immunol. 2018;9:1963. doi:10.3389/fimmu.2018.01963.30283434 11.StrÃ¶herU, DiCaroA, LiY, StrongJE, AokiF, PlummerF, FeldmannHSevere" exact="acute" post="respiratory syndrome-related coronavirus is inhibited by interferon-Î±. J Infect"/>
  <result pre="2018;9:1963. doi:10.3389/fimmu.2018.01963.30283434 11.StrÃ¶herU, DiCaroA, LiY, StrongJE, AokiF, PlummerF, FeldmannHSevere acute" exact="respiratory" post="syndrome-related coronavirus is inhibited by interferon-Î±. J Infect Dis."/>
  <result pre="of the anti-viral effects of interferon-Î± against a SARS-like coronoavirus" exact="infection" post="in vitro. Cell Res. 2006;16(2):220â€&quot;29. doi:10.1038/sj.cr.7310030.16474437 13.HaagmansBL, KuikenT, MartinaBE,"/>
  <result pre="13.HaagmansBL, KuikenT, MartinaBE, FouchierRA, RimmelzwaanGF, Van AmerongenG, TashiroMPegylated interferon-Î± protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaques. Nat Med."/>
  <result pre="AmerongenG, TashiroMPegylated interferon-Î± protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques. Nat Med. 2004;10(3):290â€&quot;93. doi:10.1038/nm1001.14981511 14.LoutfyMR, BlattLM, SiminovitchKA,"/>
  <result pre="SiminovitchKA, WardS, WolffB, LhoH, KainKCInterferon alfacon-1 plus corticosteroids in severe" exact="acute" post="respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222â€&quot;28. doi:10.1001/jama.290.24.3222.14693875 15.WalmsleyS,"/>
  <result pre="WardS, WolffB, LhoH, KainKCInterferon alfacon-1 plus corticosteroids in severe acute" exact="respiratory" post="syndrome: a preliminary study. JAMA. 2003;290(24):3222â€&quot;28. doi:10.1001/jama.290.24.3222.14693875 15.WalmsleyS, BernsteinB,"/>
  <result pre="BeallG, RuaneP, BrunSLopinavirâ€&quot;ritonavir versus nelfinavir for the initial treatment of" exact="HIV infection." post="New Engl J Med. 2002;346(26):2039â€&quot;46. doi:10.1056/NEJMoa012354.12087139 16.PulidoF, ArribasJR, DelgadoR,"/>
  <result pre="of the binding abilities of ritonavir and lopinavir to wuhan" exact="pneumonia" post="coronavirus proteases. BioRxiv. 2020. doi:10.1101/2020.01.31.929695. 18.ChuCM, ChengVCC, HungIFN, WongMML,"/>
  <result pre="of arbidol and its derivatives against the pathogen of severe" exact="acute" post="respiratory syndrome in the cell cultures. Voprosy Virusol. 2008;53:9â€&quot;13."/>
  <result pre="arbidol and its derivatives against the pathogen of severe acute" exact="respiratory" post="syndrome in the cell cultures. Voprosy Virusol. 2008;53:9â€&quot;13. 22.WangZ,"/>
  <result pre="and its derivatives against the pathogen of severe acute respiratory" exact="syndrome" post="in the cell cultures. Voprosy Virusol. 2008;53:9â€&quot;13. 22.WangZ, ChenX,"/>
  <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatment. Biosci Trend."/>
  <result pre="PengW, WangW, ChenXTherapeutic and triage strategies for 2019 novel coronavirus" exact="disease" post="in fever clinics. Lancet Respir Med. 2020;8(3):e11â€&quot;e12. doi:10.1016/S2213-2600(20)30071-0.32061335 24.ZhangL,"/>
  <result pre="doi:10.1016/S2213-2600(20)30071-0.32061335 24.ZhangL, LiuYPotential interventions for novel coronavirus in China: a" exact="systemic" post="review. J Med Virol. 2020;92:479â€&quot;90. doi:10.1002/jmv.25707.32052466 25.ZhangN, WangL, DengX,"/>
  <result pre="DengX, LiangR, SuM, HeC, DuLRecent advances in the detection of" exact="respiratory" post="virus infection in humans. J Med Virol. 2020;92(4):408â€&quot;17. doi:10.1002/jmv.25674.31944312"/>
  <result pre="LiangR, SuM, HeC, DuLRecent advances in the detection of respiratory" exact="virus infection" post="in humans. J Med Virol. 2020;92(4):408â€&quot;17. doi:10.1002/jmv.25674.31944312 26.XuXW, WuXX,"/>
  <result pre="SuM, HeC, DuLRecent advances in the detection of respiratory virus" exact="infection" post="in humans. J Med Virol. 2020;92(4):408â€&quot;17. doi:10.1002/jmv.25674.31944312 26.XuXW, WuXX,"/>
  <result pre="Bmj. 2020;368:m606. doi:10.1136/bmj.m606.32075786 27.AgostiniML, AndresEL, SimsAC, GrahamRL, SheahanTP, LuX, RayASCoronavirus" exact="susceptibility to" post="the anti-viral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the anti-viral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221â€&quot;18. doi:10.1128/mBio.00221-18.29511076 28.de"/>
  <result pre="Engl J Med. 2020;382:929â€&quot;36. doi:10.1056/NEJMoa2001191.32004427 30.LiH, LiuSM, YuXH, TangSL, TangCKCoronavirus" exact="disease" post="2019 (COVID-19): current status and future perspective. Int J"/>
  <result pre="intranasal immunization with recombinant parainfluenza virus 5 expressing middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal"/>
  <result pre="immunization with recombinant parainfluenza virus 5 expressing middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV"/>
  <result pre="KimD, RyuYBDiarylheptanoids from Alnus japonica inhibit papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirus. Biol Pharm Bull. 2012;35:2036â€&quot;42. doi:10.1248/bpb.b12-00623.22971649 33.ChenL,"/>
  <result pre="RyuYBDiarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirus. Biol Pharm Bull. 2012;35:2036â€&quot;42. doi:10.1248/bpb.b12-00623.22971649 33.ChenL, GuiC,"/>
  <result pre="from Alnus japonica inhibit papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirus. Biol Pharm Bull. 2012;35:2036â€&quot;42. doi:10.1248/bpb.b12-00623.22971649 33.ChenL, GuiC, LuoX,"/>
  <result pre="ChenJCinanserin is an inhibitor of the 3C-like proteinase of severe" exact="acute" post="respiratory syndrome coronavirus and strongly reduces virus replication in"/>
  <result pre="is an inhibitor of the 3C-like proteinase of severe acute" exact="respiratory" post="syndrome coronavirus and strongly reduces virus replication in vitro."/>
  <result pre="an inhibitor of the 3C-like proteinase of severe acute respiratory" exact="syndrome" post="coronavirus and strongly reduces virus replication in vitro. J"/>
  <result pre="2003;426(6965):450â€&quot;54. doi:10.1038/nature02145.14647384 38.SimmonsG, ReevesJD, RennekampAJ, AmbergSM, PieferAJ, BatesPCharacterization of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc"/>
  <result pre="doi:10.1038/nature02145.14647384 38.SimmonsG, ReevesJD, RennekampAJ, AmbergSM, PieferAJ, BatesPCharacterization of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl"/>
  <result pre="BatesPCharacterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated" exact="viral" post="entry. Proc Natl Acad Sci. 2004;101(12):4240â€&quot;45. doi:10.1073/pnas.0306446101.15010527 39.ShanmugarajB, SiriwattananonK,"/>
  <result pre="40.SuiJ, LiW, MurakamiA, TaminA, MatthewsLJ, WongSK, AndersonLJPotent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human mAb to"/>
  <result pre="LiW, MurakamiA, TaminA, MatthewsLJ, WongSK, AndersonLJPotent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human mAb to S1"/>
  <result pre="MurakamiA, TaminA, MatthewsLJ, WongSK, AndersonLJPotent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
  <result pre="XuKF, WeiY, JiangCAnti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal model. Cell"/>
  <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal model. Cell Res. 2013;23(2):300â€&quot;02. doi:10.1038/cr.2012.165.23208422 42.VincentMJ,"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res. 2013;23(2):300â€&quot;02. doi:10.1038/cr.2012.165.23208422 42.VincentMJ,"/>
  <result pre="RollinPE, KsiazekTG, NicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. 2005;2(1):69. doi:10.1186/1743-422X-2-69.16115318 43.WangM, CaoR, ZhangL,"/>
  <result pre="FathiA, KupkeA, KrÃ¤hlingV, OkbaNM, HesterkampTSafety and immunogenicity of a modified" exact="vaccinia" post="virus Ankara vector vaccine candidate for Middle East respiratory"/>
  <result pre="modified vaccinia virus Ankara vector vaccine candidate for Middle East" exact="respiratory" post="syndrome: an open-label, phase 1 trial. The Lancet Infect"/>
  <result pre="ZhengX, WangX, WangC, WangH, GaiW, XiaXDNA vaccine encoding Middle East" exact="respiratory" post="syndrome coronavirus S1 protein induces protective immune responses in"/>
  <result pre="WangX, WangC, WangH, GaiW, XiaXDNA vaccine encoding Middle East respiratory" exact="syndrome" post="coronavirus S1 protein induces protective immune responses in mice."/>
  <result pre="BaiB, ZhangZ, ChenY, WangHInduction of specific immune responses by severe" exact="acute" post="respiratory syndrome coronavirus spike DNA vaccine with or without"/>
  <result pre="ZhangZ, ChenY, WangHInduction of specific immune responses by severe acute" exact="respiratory" post="syndrome coronavirus spike DNA vaccine with or without interleukin-2"/>
  <result pre="ChenY, WangHInduction of specific immune responses by severe acute respiratory" exact="syndrome" post="coronavirus spike DNA vaccine with or without interleukin-2 immunization"/>
  <result pre="Nidoviruses. Washington (DC): ASM Press; 2008 p. 279â€&quot;98. 57.JordanBVaccination against" exact="infectious" post="bronchitis virus: a continuous challenge. Vet Microbiol. 2017;206:137â€&quot;43. doi:10.1016/j.vetmic.2017.01.002.28081857"/>
  <result pre="Washington (DC): ASM Press; 2008 p. 279â€&quot;98. 57.JordanBVaccination against infectious" exact="bronchitis" post="virus: a continuous challenge. Vet Microbiol. 2017;206:137â€&quot;43. doi:10.1016/j.vetmic.2017.01.002.28081857 58.LiuC,"/>
  <result pre="LamirandeEW, MurphyBR, SubbaraoK, CollinsPLContributions of the structural proteins of severe" exact="acute" post="respiratory syndrome coronavirus to protective immunity. Proc Natl Acad"/>
  <result pre="MurphyBR, SubbaraoK, CollinsPLContributions of the structural proteins of severe acute" exact="respiratory" post="syndrome coronavirus to protective immunity. Proc Natl Acad Sci."/>
  <result pre="SubbaraoK, CollinsPLContributions of the structural proteins of severe acute respiratory" exact="syndrome" post="coronavirus to protective immunity. Proc Natl Acad Sci. 2004;101(26):9804â€&quot;09."/>
  <result pre="immunity. Proc Natl Acad Sci. 2004;101(26):9804â€&quot;09. doi:10.1073/pnas.0403492101.15210961 60.SchindewolfC, MenacheryVDMiddle East" exact="respiratory" post="syndrome vaccine candidates: cautious optimism. Viruses. 2019;11(1):74. doi:10.3390/v11010074. 61.MarkD.Live"/>
  <result pre="Proc Natl Acad Sci. 2004;101(26):9804â€&quot;09. doi:10.1073/pnas.0403492101.15210961 60.SchindewolfC, MenacheryVDMiddle East respiratory" exact="syndrome" post="vaccine candidates: cautious optimism. Viruses. 2019;11(1):74. doi:10.3390/v11010074. 61.MarkD.Live attenuated"/>
  <result pre="[accessed 2020 614]. https://patentimages.storage.googleapis.com/b5/d4/fb/5d1a763f553801/US20060039926A1.pdf. 62.collab: WHO, COVID-2019 (World Health Organization)Coronavirus" exact="disease" post="(COVID-2019) situation reports. 2020 [accessed 2020 422]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. 63.SmithG,"/>
  <result pre="2020 [accessed 2020 422]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. 63.SmithG, LiuY, MassareM.Immunogenic middle east" exact="respiratory" post="syndrome coronavirus (mers-cov) compositions and methods. WO2015042373A1. 2015326 [accessed"/>
  <result pre="[accessed 2020 422]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. 63.SmithG, LiuY, MassareM.Immunogenic middle east respiratory" exact="syndrome" post="coronavirus (mers-cov) compositions and methods. WO2015042373A1. 2015326 [accessed 2020"/>
  <result pre="26http://ir.novavax.com/news-releases/news-release-details/novavax-advances-developmentnovel-covid-19-vaccine. 65.WuT-C, HungC-F, KimTWDNA vaccines targeting antigens of the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV). WO2005081716A3. 200599 [accessed 2020 614]."/>
  <result pre="65.WuT-C, HungC-F, KimTWDNA vaccines targeting antigens of the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV). WO2005081716A3. 200599 [accessed 2020 614]. https://patentimages.storage.googleapis.com/75/0f/29/7245823f01f88f/WO2005081716A3.pdf."/>
  <result pre="HungC-F, KimTWDNA vaccines targeting antigens of the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV). WO2005081716A3. 200599 [accessed 2020 614]. https://patentimages.storage.googleapis.com/75/0f/29/7245823f01f88f/WO2005081716A3.pdf. 66.WeinerDB,"/>
  <result pre="BleickerTClinical presentation and virological assessment of hospitalized cases of coronavirus" exact="disease" post="2019 in a travel-associated transmission cluster. MedRxiv. 2020. doi:10.1101/2020.03.05.20030502."/>
 </snippets>
</snippetsTree>
